His lab specializes in the adaptation of proteomic and functional genomic technologies to primary models of disease to better understand the molecular dynamics of the host-pathogen relationship. His work on CRISPR technologies with Dr. Nevan Krogan at the University of California, San Francisco led to the development of the first gene editing platform for primary CD4+ T cells, the identification of several novel pathways that contribute to HIV replication, and the discovery of a new class of CRISPR inhibitors encoded by bacteriophages that maintain their function in mammalian cells. He is currently funded by the Third Coast Center for AIDS Research (CFAR) and the American Foundation for AIDS Research (amFAR) to apply CRISPR-Cas9 RNP technology to uncover the molecular mechanisms that underlie HIV latency and reactivation in patient reservoirs.